Class Action Reminder for NMRA Investors: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors of Securities Fraud Class Action Lawsuit

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering on September 15, 2023 [1] Group 1: Allegations Against Neumora - The lawsuit claims that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2] - It is alleged that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2] - The complaint states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which affected the ability to predict results of the KOASTAL-1 study accurately [2] Group 2: Lead Plaintiff Process - Neumora investors can seek to be appointed as a lead plaintiff representative of the class by April 7, 2025, or may choose to remain absent [3] - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [3] - The decision to serve as a lead plaintiff does not affect the ability to share in any recovery from the lawsuit [3] Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages Neumora investors who have suffered losses to contact them for more information [4] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]